Включение тиазидного диуретика в комбинированную антигипертензивную терапию целесообразно
Аннотация
В статье рассматриваются основания для включения тиазидных (и тиазидоподобных) диуретиков (тД) в состав комбинированной терапии при артериальной гипертонии на примере комбинации β-адреноблокатора (β-АБ) бисопролола и тД гидрохлортиазида. Подчеркивается необходимость включения тД в дозах, не вызывающих нарушение толерантности к глюкозе и не оказывающих неблагоприятное действие на липидный профиль. На примере препарата Лодоз® подчеркивается целесообразность наличия различных доз β-АБ в комбинации с тД, что расширяет возможности врача при назначении комбинированной терапии.
Список литературы
1. Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России: информированность, лечение, контроль. Профил забол укреп здор 2001; 2: 3-7.
2. Оганов Р.Г. Развитие профилактической кардиологии в России. Кардиоваск тер профил 2004; 3(3), ч.1: 10-4.
3. Neuton JD, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study. JAMA 1993; 270: 713-24.
4. SHEP Cooperative Reseach Group. Prevention of stroke by antihypertensive drug treatment in older person withisolated systolis hypertension. Final results of the Systolic Hypertension in Elderly Program (SHEP). JAMA 1991; 265: 3255-64.
5. Dahlof B, LindholmLH, HanssonL, etal. Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-Hypertension). Lancet 1991; 338: 1281-5.
6. Medical research council worcing party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97-104.
7. The ALLHAT officers and coordinators for the ALLHAT collaborative reseach group.Major outcomes in bighrisk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calciumchannel blocker vs diuretic. JAMA 2002; 288: 2981-97.
8. Taylor AL, Wright JT. Importance of Race/Ethnicy in Clinical Trials. Lesson From the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT). Circulation 2005; 112: 3654-66.
9. Sleight P, Yusuf S. New evidence on the importance of renninangiotensin system in the treatment of higher-risk patiens with hypertension. J Hypertens 2003; 21(9): 1599-608.
10. Psaty BM. Health outcomes associated with various antihypertensive therapies used as a first line agents. A Network meta-analysis. JAMA 2003; 289: 2534-44.
11. Dahlof B, Sever PS, PoulterNR, etal. Prevention of cardiovascular events with an antihypertensive regimes of amlodipine adding perindopril as reguired versus atenjlol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial -Blood Pressure Lowering Arm (ASCOT-BPLA): a muticentre randomised controlled trial. Lnced 2005; 366: 895-906.
12. Dahlof D, Devereux RB, Kjeldsen, etal. Cardiovascular morbidity and mortality in the losartan intervention for Endpoint reduction in hypertension study (LIFE). Lancet 2002; 359: 995-1003.
13. Pepine CJ, Handberg-Thurmond E, et al. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST). JACC 1998; 32: 1228-37.
14. Mercuri M, Henning M, Zanchetti A, et al. Several articles presenting the different aspects of ELSA Blood Press 1996; 5(Suppl 4): 20-52.
15. Mancia G, Grasswi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J of Hypertens 2006; 24: 3-10.
16. Недогода С.В. Комбинированная антигипертензивная терапия: есть ли шансы у ЛОДОЗА? Фарматека 2008; 15: 9-14.
17. Jounela AJ, Lilya M, Lumme J. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effect. Blood Press 1994; 3(4): 231-5.
18. Sarafidis P, Barkis GL. Antihypertensive therapy and the risk of new-onset diabetes. Diabetes care 2006; 29: 1167-9.
19. Fernandez JG, Rodriguez-Perez JC, Garrido J, et al. Effect of two antihypertensive combinations on metabolic control in type-2 dibetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001; 15: 849-56.
20. Schneider M. Metabolic neutralitymof combined verapamil-trandolapril tratment in contrast to beta-blocker-low dose and chlortalidone in hypertensive type 2 diabetes. J Hypertens 1996; 14: 669-77.
21. 2007 Guidelines for the Management of Arterial Hypertension. J of Hypertens 2007; 25: 1105-87.
22. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987; 8: 103-13.
23. Buhtel FR, Berglund G, Anderson OK, et al. Smoking status and cardioselective beta-blocade antihypertensive therapy: the Bisoprolol International Multicentre Study (BIMS). J Hypertens 1986; 4: 144-6.
24. Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind trial. Eur Heart J 1987; 8(Suppl.M): 65-9.
25. Van der Ven LM. Age-dependent differences in the efficacy and tolerability of different classes of antihypertensive drugs. Clin Drug Invest 1997; 1: 16-22.
26. Mengden T, Vetter W. The efficacy of bisoprolol in the treatment of hypertension. Rev Contemp Pharmacother 1997; 8: 55-67.
27. FrishmanWH, Brizzynski BS, Coulson LR, et al. A multifactorial trial design to assess cjmbination therapy in hypertension: treatment with Bissoprolol and Hydrochlorothiazide. Arch Intern Med 1994; 154: 1461-8.
28. Frishman WH, Burris Jf, Mroczek WJ, et al. First-line therapy jhtion with lowe0dose Bisoprolol fumarate and lowe-dose Hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol 1995; 35: 182-8.
29. Neutel JM, Rolf CN, Valentine SN, et al. Low-dose combination therapy as fist line treatment of mild to moderate hypertension: the efficacy and safety of Bisoprolol/6,25 HCTZ versus Amlodipine, Enalapril and placebo. Cardiovasc Rev Rep 1996; 17: 33-45.
30. Prisant LM, Weir MR, Papademetriou V, et al. Low-dose drug combination therapy: an alternative forst-line approach to hyperttension treatment. Am Heart J 1995; 130: 359-66.
31. Papademetriou V, Neutel JM, Narayan P, et al. Comparison of Bisoprolol and low-dose Hydrochlorohtiazide combination with Losartan, alone or in combination Wth hydrochlorothiazide in the hreatment of hupertension; a double blind, randomized, placebo-controlled trial. CVR R 1998; 1-8.
Рецензия
Для цитирования:
Макалкии В.И. Включение тиазидного диуретика в комбинированную антигипертензивную терапию целесообразно. Кардиоваскулярная терапия и профилактика. 2008;7(8):80-84.
For citation:
Makolkin V.I. Adding а thiazide diuretic to combined antihypertensive therapy is clinically reasonable. Cardiovascular Therapy and Prevention. 2008;7(8):80-84. (In Russ.)
Просмотров:
478
Послать статью по эл. почте 
